FR EN MAIN NAVIGATION COMPANY SCIENCE PRODUCTS PARTNERING INVESTORS MEDIA CAREERS OUR NK CELL ENGAGER PLATFORM Home Science ANKET: Our NK cell engager Platform ANKET™ (Antibody-based NK cell Engager Therapeutics) is Innate’s proprietary platform for developing next-generation, multi-specific NK cell engagers to treat certain types of cancer. This versatile, fit-for-purpose technology is creating an entirely new class of molecules to induce synthetic immunity against cancer. It leverages the advantages of harnessing NK cell effector functions against cancer cells and also provides proliferation and activation signals targeted to NK cells. Our latest innovation, the tetra-specific ANKET molecule, is the first NK cell engager technology to engage activating receptors (NKp46 and CD16), a tumor antigen and an interleukin-2 receptor (via an IL-2 variant, IL-2v) via a single molecule. This innovation is built on our existing tri-specific NK cell engager technology, which has demonstrated potent NK cell activation, cytotoxicity and efficient control of tumor growth in preclinical models. Learn more about targeting NK cells and their important role in activating an anti-tumor response. How ANKET is advancing immunotherapy Development with our ANKET platform Rationale for using NKp46 and IL-2v Further Reading Publications, posters and presentations View publications Main menu Scientific approach Innate Immunity & NK cells Antibody formats ANKET: Our NK cell engager Platform Publications LATEST NEWS ON ANKET™ Innate Pharma Third Quarter 2021 Report November 16, 2021 Innate Pharma highlights new NK cell engager data with partner Sanofi at SITC annual meeting November 12, 2021 Innate Pharma Reports First Half 2021 Financial Results and Business Update September 15, 2021 All press releases Footer Contact Location Legal Info Terms of use Privacy Notice Cookies notice General Conditions of Purchase Search Search Follow us Stay in touch Subscribe to our newsletter Contact us Location 117, Avenue de Luminy - BP 30191 13 009 Marseille FRANCE +33 (0)4 30 30 30 30 Innate Pharma, Inc. 2273 Research Boulevard, Suite 350 Rockville, MD 20850, USA